Clare Arnott's Publications

About Clare Arnott's Publications

Co-Director, Cardiovascular Program
  • Co-Director, Global Chronic & Complex Diseases
  • BMed Sci,
  • MBBS (Hons),
  • PhD,
  • FRACP,
  • FESC,
  • CF

  • Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

    Diabetes Care Date published:

  • Multidisciplinary perspectives on the role of primary care in managing chronic breathlessness

    01.03 - General practice and primary care Date published:

  • Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program

    Diabetes, Obesity and Metabolism Date published:

  • Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

    Journal of the American Heart Association Date published:

  • Radial First in Primary Percutaneous Coronary Intervention-Ensuring At-Risk Groups Aren’t Left Behind

    Heart, Lung and Circulation Date published:

  • The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial

    Diabetes & Metabolism Date published:

  • Mechanisms of action of the sodium-glucose cotransporter-2 ( SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial

    Diabetes, Obesity and Metabolism Date published:

  • Optimising mothers’ health behaviour after hypertensive disorders of pregnancy: a qualitative study of a postnatal intervention

    BMC Public Health Date published:

  • Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis

    Diabetes, Obesity and Metabolism Date published:

  • 862-P: Interleukin-6 and Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Post Hoc Analysis of CANVAS Trial

    Diabetes Date published:

  • Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial

    Journal of Diabetes Research Date published:

  • Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials

    Circulation Date published:

  • Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial

    Clinical Journal of the American Society of Nephrology Date published:

  • Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease

    Clinical Journal of the American Society of Nephrology Date published:

  • Colchicine in Cardiovascular Disease: In-Depth Review

    Circulation Date published: